Indivior Pharmaceuticals, Inc. (INDV) Stock
5 of the hedge funds AlphaScala tracks reported INDV in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $109.46M. Company insiders reported 2 open-market buys and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own INDV?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 2.67M | $109.46M | -25% |
| Millennium Management Israel Englander | 2.10M | $86.12M | -54% |
| Point72 Steve Cohen | 1.25M | $51.31M | +1217% |
| D.E. Shaw David Shaw | 236K | $9.68M | +16% |
| Bridgewater Associates Ray Dalio | 68K | $2.80M | +84% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Indivior Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 27, 26 | Anderson Woodrow D | Chief Accounting Officer | BUY | 1.5K | $54K |
| Aug 5, 26 | Anderson Woodrow D | Chief Accounting Officer | BUY | 1.5K | $54K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →INDV price chart
Powered by TradingViewWhat does Indivior Pharmaceuticals, Inc. do?
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing buprenorphine-based prescription medications for treating opioid use disorder and related substance dependence. Its core products include SUBLOCADE, a once-monthly extended-release buprenorphine injection designed for long-acting treatment, and SUBOXONE Film, a sublingual film combining buprenorphine and naloxone for maintenance therapy. These treatments target patients seeking effective options to manage opioid dependence, addressing a critical public health need. Indivior Pharmaceuticals, Inc. operates in key markets including the United States, Europe, Canada, Australia, and other international regions, with a primary emphasis on the U.S. where demand for such therapies is substantial. The company specializes in the addiction treatment segment, providing innovative formulations that improve patient adherence and outcomes compared to daily dosing alternatives. Founded in 2014 and headquartered in North Chesterfield, Virginia, Indivior Pharmaceuticals, Inc. plays a vital role in the global effort to combat the opioid crisis through targeted pharmacotherapies.